Latest News on NAGE

Financial News Based On Company

Want to find fair value of NAGE?

Niagen Bioscience ( NAGE ) Surpasses Q3 Earnings and Revenue Estimates

https://www.zacks.com/stock/news/2785057/niagen-bioscience-nage-surpasses-q3-earnings-and-revenue-estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +150.00% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Recursion Pharmaceuticals ( RXRX ) Q3 Earnings Expected to Decline

https://www.zacks.com/stock/news/2780287/earnings-preview-recursion-pharmaceuticals-rxrx-q3-earnings-expected-to-decline

Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Niagen Bioscience ( NAGE ) Reports Next Week: What to Expect

https://www.zacks.com/stock/news/2779062/niagen-bioscience-nage-reports-next-week-what-to-expect

Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Niagen Bioscience ( NAGE ) Q2 Earnings and Revenues Surpass Estimates

https://www.zacks.com/stock/news/2675123/niagen-bioscience-nage-q2-earnings-and-revenues-surpass-estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Niagen NAGE Q2 2025 Earnings Call Transcript

https://www.fool.com/earnings/call-transcripts/2025/08/06/niagen-nage-q2-2025-earnings-call-transcript/

Image source: The Motley Fool.Aug. 6, 2025, 8:30 p.m. ETChief Executive Officer - Rob FriedContinue reading ...

Major Update: Frank Jaksch Jr At Niagen Bioscience Exercises Options, Realizing $0 - Niagen Bioscience ( NASDAQ:NAGE )

https://www.benzinga.com/insights/news/25/06/46118162/major-update-frank-jaksch-jr-at-niagen-bioscience-exercises-options-realizing-0

Frank Jaksch Jr, Board Member at Niagen Bioscience NAGE, reported a large exercise of company stock options on June 26, according to a new SEC filing. What Happened: In an insider options sale disclosed in a Form 4 filing on Thursday with the U.S.

Options Exercise Update At Niagen Bioscience: Ann Cohen Engages, Resulting In $0 - Niagen Bioscience ( NASDAQ:NAGE )

https://www.benzinga.com/insights/news/25/06/46118160/options-exercise-update-at-niagen-bioscience-ann-cohen-engages-resulting-in-0

In a new SEC filing on June 26, it was revealed that Cohen, Director at Niagen Bioscience NAGE, executed a significant exercise of company stock options. What Happened: A Form 4 filing from the U.S.

Options Exercise Update At Niagen Bioscience: Jeong James Lee Attorney-in-Fact Engages, Resulting In $0 - Niagen Bioscience ( NASDAQ:NAGE )

https://www.benzinga.com/insights/news/25/06/46118156/options-exercise-update-at-niagen-bioscience-jeong-james-lee-attorney-in-fact-engages-resulting-in-

A large exercise of company stock options by Jeong James Lee Attorney-in-Fact, Board Member at Niagen Bioscience NAGE was disclosed in a new SEC filing on June 26, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.

Steven Rubin At Niagen Bioscience Exercises Options Worth $0 - Niagen Bioscience ( NASDAQ:NAGE )

https://www.benzinga.com/insights/news/25/06/46118154/steven-rubin-at-niagen-bioscience-exercises-options-worth-0

On June 26, it was revealed in an SEC filing that Steven Rubin, Director at Niagen Bioscience NAGE executed a significant exercise of company stock options. What Happened: Rubin, Director at Niagen Bioscience, made a strategic move by exercising stock options for 0 shares of NAGE as detailed in a ...

Niagen Bioscience ( NAGE ) Q1 Earnings and Revenues Beat Estimates

https://www.zacks.com/stock/news/2464574/niagen-bioscience-nage-q1-earnings-and-revenues-beat-estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 100% and 13.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Robert Fried Exercises Options, Realizes $173K - Niagen Bioscience ( NASDAQ:NAGE )

https://www.benzinga.com/insights/news/25/04/44739279/robert-fried-exercises-options-realizes-173k

A large exercise of company stock options by Robert Fried, Chief Executive Officer at Niagen Bioscience NAGE was disclosed in a new SEC filing on April 9, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.

Manual One-Time Payment

Use this form to send a single payment (e.g., $5, $10, $15, etc.) for any agreed amount such as partial subscription catch-up, small adjustments, or one-off services.

Regular subscriptions are charged automatically through your plan. This form is only for extra one-time payments when requested.

Disclaimer

The Value-Trades website is intended for informational purposes only. The content provided on this website, including but not limited to recommendations, analysis, and opinions, should not be considered financial advice. Before making any investment decisions, whether buying or selling, based on information obtained from this website, it is imperative that you conduct your own thorough due diligence. This includes consulting with a qualified financial advisor, reviewing financial statements, and understanding the risks involved in any investment. The owner of this website shall not be held responsible for any financial losses incurred as a result of using the information provided herein. Investing in financial markets involves risk, and past performance is not indicative of future results. You are solely responsible for your investment decisions.